Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis

IMPORTANCE: Although BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (BCR-ABL TKIs) can substantially improve the survival rate of chronic myeloid leukemia (CML), they are clinically accompanied by severe hepatotoxicity. OBJECTIVE: To compare the relative risk (RR) of hepatotoxicity of new-gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhe, Wang, Xiaoyu, Wang, Zhen, Feng, Yuyi, Jia, Yaqin, Jiang, Lili, Xia, Yangliu, Cao, Jun, Liu, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299317/
https://www.ncbi.nlm.nih.gov/pubmed/34292334
http://dx.doi.org/10.1001/jamanetworkopen.2021.20165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299317/
https://www.ncbi.nlm.nih.gov/pubmed/34292334
http://dx.doi.org/10.1001/jamanetworkopen.2021.20165

Ejemplares similares